RACK1 is the founding member of a family of receptors for activated C kinase collectively called RACKs. Upon activation of PKC, RACK1 co-localizes with the Src tyrosine kinase at the plasma membrane and functions as a substrate, binding partner and inhibitor of Src (as measured in vitro), and a growth inhibitor in NIH 3T3 cells. To further analyze the function of RACK1 in Src and PKC signaling, we utilized cell-permeable peptides that modulate the interaction of RACK1 and bIIPKC, thereby affecting bIIPKC translocation and function. We found that the association of bIIPKC and RACK1 is necessary for Src phosphorylation of RACK1. Src activity is required for tyrosine phosphorylation of RACK1, and for RACK1 binding to Src, but not to bIIPKC. Endogenous Src kinase activity, as measured by phosphorylation of Sam68 (a mitotic-specific Src substrate involved in cell cycle regulation and RNA splicing) or p190RhoGAP (a Src substrate and GTPase-activating protein involved in actin reorganization), increases with disruption of the Src-RACK1 complex, and decreases with enhanced complex formation. RACK1 inhibits Srcmediated p190RhoGAP signaling and actin cytoskeleton rearrangement. Thus, RACK1 functions as an endogenous inhibitor of the Src kinase in diverse signaling pathways that regulate distinct cellular functions. Our results demonstrate the potential for using peptide modulators of Src activity as a tool for uncovering the function of Src in cells.
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Oncogene ( Keywords: Src; tyrosine kinase; RACK1; PKC; Sam68; p190RhoGAP When regulated, the Src tyrosine kinase participates in a wide array of signaling pathways that control cell proliferation, differentiation, adhesion and survival (reviewed in Thomas and Brugge, 1997) . Deregulated Src is oncogenic (Cartwright et al., 1987; Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987; Reynolds et al., 1987) . Therefore, it is important to identify mechanisms that regulate Src. In doing so, we will learn how normal cells regulate their growth.
PKC is a family of serine/threonine kinases (reviewed in Newton, 1995) . Upon activation, PKC isozymes translocate to different subcellular sites where they phosphorylate specific substrates that mediate distinct cellular functions. Isozyme specificity appears to be mediated, in part, by association with specific adaptor proteins (reviewed in Mochly-Rosen, 1995; Schechtman and Mochly-Rosen, 2001 ). RACK1, the first PKCadaptor protein to be identified, is homologous to the b subunit of heterotrimeric G proteins, and both proteins are members of an ancient family of regulatory proteins made up of highly conserved WD repeats. RACK1 is located in the cell particulate fraction, binds PKC at a site distinct from the substrate-binding site, and is neither a substrate nor inhibitor of PKC (Ron et al., 1994 ). RACK1 appears to be required for the translocation of cytosolic bIIPKC to the cell particulate fraction where bIIPKC-specific substrates are located.
Cell-permeable peptides function as agonists or antagonists of PKC when introduced into cells (reviewed in Souroujon and Mochly-Rosen, 1998; Dorn and Mochly-Rosen, 2002) . The antagonist peptide bC2-4 (corresponding to amino acids 218-226 in bPKC) competes with bPKCs for binding to RACK1, and inhibits phorbol ester-induced translocation of the C2-containing isozymes in cardiac myocytes, and insulininduced bPKC translocation and function in Xenopus oocytes . The antagonist peptide bIIV5-3 (corresponding to amino acids 645-650 in bIIPKC) competes selectively with bIIPKC for binding to RACK1 and inhibits PMA-induced translocation of bIIPKC and cardiac myocyte hypertrophy in phorbol-12-myristate-13-acetate (PMA)-treated cells (Stebbins and Mochly-Rosen, 2001 ). The pseudo-RACK1 peptide acts as a PKC agonist by binding to the inactive form of PKC and inducing conformation changes required for activation and translocation of the enzyme .
Upon PKC activation with PMA, RACK1 colocalizes with Src at the plasma membrane of NIH 3T3 cells (Chang et al., 2001) . Stimulation of these cells with serum, PDGF or PMA enhances the tyrosine phosphorylation of RACK1 and the binding of RACK1 to Src. RACK1 functions as a substrate, binding partner and inhibitor of the Src tyrosine kinase (as measured in vitro), and a growth inhibitor in NIH 3T3 cells (Chang et al., 1998 (Chang et al., , 2001 (Chang et al., , 2002 . These findings reveal an interesting intersection between Src and PKC signaling pathways, and suggest that RACK1 is a common link. However, the influence of RACK1 on the endogenous activity of Src, and on cross talk between Src and PKC signaling pathways is unknown.
To further define the function of RACK1 in these signaling pathways, we first assessed binding of RACK1 to Src and to PKC isozymes (Figure 1a) . RACK1 bound Src (lane 1), bIIPKC (lane 3) and to a lesser extent bIPKC (lane 4), but not aPKC (lane 2) or protein 14-3-3 (lane 5). Protein 14-3-3 is a phosphoserine/phosphotyrosine-binding protein that controls the function of many cellular proteins (Aitken et al., 2002) , and was used here as an example of a signaling protein that does not belong to the PKC family. As expected, RACK1 was not detected in IgG immunoprecipitates (lane 6).
Next, we utilized the bPKC peptides to assess the influence of bIIPKC on Src phosphorylation of, and binding to, RACK1. In agreement with previous findings, we observed that RACK1 bound bIIPKC in the absence of peptide ( Figure 1b , lane 1) and in the presence of carrier (control) peptide (lane 2), but not in the presence of the bC2-4 (lane 3) or bIIV5-3 (lane 4) antagonist peptides. RACK1 also bound Src and was tyrosine phosphorylated in the absence of peptide (lanes 5 and 11, respectively) and in the presence of carrier peptide (lanes 6 and 12, respectively), but not in the presence of either bPKC-selective antagonist peptide (lanes 7 and 8 or 13 and 14, respectively). In contrast, incubation of cells with the bPKC agonist peptide increased binding of bIIPKC to RACK1 (Figure 1c ; compare lane 3 with 1 and 2), binding of Src to RACK1 (compare lane 6 with 4 and 5) and tyrosine phosphorylation of RACK1 (compare lane 9 with 7 and 8). Additional immunoblot analyses showed that Src immunoprecipitates contained equivalent amounts of Src protein, and bIIPKC immunoprecipitates contained equivalent amounts of bIIPKC protein (data not shown). These results indicate that the association of bIIPKC and RACK1 is necessary for Src phosphorylation of, and binding to, RACK1.
Next, we utilized the bPKC peptides to analyze the interplay between Src, bIIPKC and RACK1 in signaling complexes ( Figure 1d ). We observed that addition of the bPKC antagonist peptides not only prevented binding of RACK1 to bIIPKC (Figure 1d , middle panel) and to Src (lower panel), but also prevented binding of Src to bIIPKC, as assessed in Src immunoprecipitates (upper panel). The latter was also true when assessed in bIIPKC immunoprecipitates (data not shown). Conversely, addition of the bPKC agonist peptide not only promoted binding of RACK1 to bIIPKC and to Src but also promoted binding of Src to bIIPKC (Figure 1d , compare lane 4 with 1). These results suggest that RACK1, Src to bIIPKC function together in a signaling complex, and that bIIPKC binding to RACK1 regulates Src binding to the complex.
To determine whether Src activity is required for the tyrosine phosphorylation of RACK1, we utilized two Src-specific kinase inhibitors, SU6656 (Blake et al., 2000) and PP2 (Hanke et al., 1996) , and assessed their influence on Src in vitro kinase activity, tyrosine phosphorylation of RACK1, and the interaction of were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum, and were incubated with 16 nM PMA for 15 min prior to lysis in NP40 buffer (0.5% NP-40, 20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA, 100 mM sodium vanadate, 50 mM sodium fluoride, 50 mM leupeptin, 1% aprotinin and 1 mM dithiothreitol). Lysates of total cellular proteins or immunoprecipitates were analysed by protein immunoblotting after SDS-PAGE with the specified antibody as described (Chang et al., 1998 (Chang et al., , 2001 (Chang et al., , 2002 . Primary antibodies: mouse monoclonal antibodies to Src (MAB 327; Lipsich et al., 1983) , RACK1, phosphotyrosine (PY20) (Transduction Laboratories, Lexington, KY, USA) and protein 14-3-3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and rabbit polyclonal antisera to PKC isozymes a, bI and bII (Santa Cruz Biotechnology). (Figure 2a, compare lanes 1 and 2) . Similarly, treatment of cells with PP2, but not its inactive analog PP3, significantly inhibited Src in vitro kinase activity (compare lanes 3 and 4). Treatment with SU6656 or PP2 also inhibited the tyrosine phosphorylation of RACK1 (Figure 2b , compare lanes 5 and 6 or 7 and 8, respectively) and the interaction of RACK1 with Src (compare lanes 1 and 2 or 3 and 4, respectively). In contrast, the Src inhibitors had no effect on the interaction of RACK1 with bIIPKC (Figure 2c, compare lanes 1 and 2 or 3 and 4) . Together, these results demonstrate that Src kinase activity is required for the tyrosine phosphorylation of RACK1 and for the interaction of RACK1 with Src, but not with bIIPKC.
Next, we utilized the peptide modulators of the Src-RACK1 interaction as a tool for dissecting the influence of RACK1 on the kinase activity of Src. Again, we observed that the bPKC antagonist peptides inhibited the tyrosine phosphorylation of RACK1 (Figure 3 , panel a) and the binding of Src to RACK1 (Figure 1d , bottom panel). The bPKC antagonist peptides also increased the in vitro kinase activity of Src (Figure 3,  panel b) . Conversely, the bPKC agonist peptide enhanced the tyrosine phosphorylation of RACK1 and the binding of Src to RACK1, and inhibited the in vitro kinase activity of Src (Figure 3, panel b) . These results provide evidence that the in vitro kinase activity of Src increases with disruption of the Src-RACK1-PKC complex and decreases with enhanced complex formation.
Sam68 is a mitotic-specific Src substrate and member of the STAR family of RNA binding proteins. It functions in signal transduction, cell cycle regulation, tumorigenesis and RNA biogenesis (reviewed in Lukong and Richard, 2003) . To assess the influence of RACK1 on the endogenous kinase activity of Src, we utilized the peptide modulators of the RACK1-Src complex and examined the tyrosine phosphorylation of Sam68. We observed that the bPKC antagonist peptides increased, whereas the bPKC agonist peptide decreased the tyrosine phosphorylation of Sam68 (Figure 3, panel c) . The peptides did not affect expression of Sam68 (panel d). Thus, the in vivo kinase activity of Src, as measured by phosphorylation of Sam68, increased with disruption of the Src-RACK1-PKC complex and decreased with enhanced complex formation. This observation on RACK1's influence on the endogenous activity of Src Figure 2 Effect of Src tyrosine kinase inhibitors on (a) Src in vitro kinase activity; (b) Src phosphorylation of, and binding to RACK1; and (c) bIIPKC binding to RACK1. NIH 3T3 cells were incubated with the Src tyrosine kinase inhibitor SU6656 (2 mM, Sugen, South San Francisco, CA, USA) or PP2 (3 mM, Calbiochem, La Jolla, CA, USA), or with PP3, an inactive analog of PP2, or buffer (À) for 2 h, and with 16 nM PMA for 15 min prior to lysis. (a) Methods to evaluate the phosphorylating activity of Src by kinase assays in vitro have been described previously (Chang et al., 1998 (Chang et al., , 2001 (Chang et al., , 2002 . Briefly, Src immunoprecipitates were incubated with [g- is consistent with those of our in vitro studies (Figure 3 , panel c); both demonstrating that the presence of RACK1 in a Src signaling complex inhibits, and the absence of RACK1 in the complex enhances Src kinase activity.
To determine the extent of RACK1's inhibitory influence on Src-mediated signaling pathways, we examined the tyrosine phosphorylation of a Src substrate that signals in a different pathway, and one that regulates different cellular processes than those involving Sam68. We focused on p190RhoGAP, a Src substrate and GTPase-activating protein involved in actin reorganization (reviewed in Donovan et al., 2002) . Upon tyrosine phosphorylation by Src, p190RhoGAP binds to p120RasGAP, which leads to downregulation of Rho activity and disassembly of actin stress fibers (Chang et al., 1995; Fincham et al., 1999) . We found that the bPKC antagonist peptides increased, whereas the bPKC agonist peptide decreased the tyrosine phosphorylation of p190RhoGAP (Figure 4a, panel 1) , and the binding of RhoGAP and RasGAP (panel 3). The peptides had no effect on expression levels of RhoGAP (panel 2) or RasGAP (panel 4). Src phosphorylation of the N-terminal domain of p190RhoGAP is known to decrease the GTP binding activity of RhoGAP (Roof et al., 1998 (Roof et al., , 2000 . Therefore, we examined the effect of the peptide modulators of Src activity on the ability of RhoGAP to bind GTP. We observed that the bPKC antagonist peptides, which increase Src activity by preventing Src binding to RACK1, decreased binding of RhoGAP to GTP (Figure 4a, panel 5) . In contrast, the bPKC agonist peptide, which decreases Src activity by promoting Src binding to RACK1, increased binding of RhoGAP to GTP. Next, we examined the effect of the peptide modulators of Src activity on the actin cytoskeleton by assessing actin stress fiber formation (Figure 4b ). We observed that incubation with the bPKC antagonist peptides, which increase Src activity by preventing Src binding to RACK1, resulted in disruption and loss of actin stress fibers (lower left and middle panels). In contrast, the bPKC agonist peptide, which decreases Src activity by promoting Src binding to RACK1, slightly induced stress fiber formation (lower right panel). Thus, RACK1 has an inhibitory effect on Src-mediated p190RhoGAP activity and actin cytoskeleton rearrangement.
This study further defines the function of RACK1 in Src and PKC signaling complexes (Figures 1 and 2 ) and identifies RACK1 as an endogenous inhibitor of the Src tyrosine kinase (Figures 3 and 4) . These findings extend our previous observations that RACK1 inhibits Src in vitro kinase activity (Chang et al., 1998) , and that PKC activation induces the co-localization of RACK1 and Src at the plasma membrane and the tyrosine phosphorylation of RACK1 (Chang et al., 2001) . They provide new information about the influence of RACK1 on Src function, and about cross talk between RACK1, Src and PKC in signaling complexes.
The finding that RACK1 inhibits phosphorylation of two functionally diverse Src substrates, Sam68 and p190RhoGAP, suggests that RACK1's influence on Src is broad-reaching, affecting Src-mediated pathways as diverse as those that regulate cell cycle progression, RNA processing and the actin cytoskeleton. These findings signify the powerful and pervasive influence that a Src inhibitor could have on control of cell proliferation, differentiation, adhesion and survival. Monoclonal antibodies that recognize p190RhoGAP or p120Ras-GAP were purchased from Transduction Laboratories. GTP overlay assays (panel 5) were performed as described (Roof et al., 2000) . Data are representative of two independent experiments. (b) Effect of bPKC antagonist and agonist peptides on actin stress fiber arrangement. Cells were grown on fibronectin (20 mg/ml)-coated chamber slides for 24 h prior to the addition of bPKC peptides and PMA. Cells were fixed in 4% paraformaldehyde in PBS for 20 min, quenched twice in 0.1 M glycine for 10 min and permeabilized in 0.4% saponin, 1% BSA and 5% goat serum for 15 min (Hay et al., 1996) . Cells were then incubated with Alexa Fluor 594 phalloidin (33 nM; Molecular Probe, Eugene, OR, USA) for 30 min in the dark. Slides were mounted with vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Data are representative of two independent experiments Studies with a temperature-dependent v-Src protein revealed the requirement of active v-Src kinase for tyrosine phosphorylation of p190RhoGAP and its binding to p120RasGAP, stimulation of p120GAP-associated RhoGAP activity and disassembly of actin stress fibers (Fincham et al., 1999) . Conversely, switching off v-Src activity results in disassociation of the p190/p120 complex, inactivation of p120-associated RhoGAP activity and re-induction of actin stress fibers. Therefore, inhibition of Src activity and consequently RhoGAP activity is important for maintaining an organized actin cytoskeleton. Our finding that RACK1 inhibits Src-mediated RhoGAP activity and actin cytoskeleton rearrangement (Figure 4 ) identifies a novel mechanism of regulation of this important pathway.
The finding that RACK1, Src and bIIPKC appear to function together in a signaling complex where RACK1 exerts an inhibitory influence on Src activity (Figures 2  and 3 ) but not on PKC activity (Ron et al., 1994) indicates that RACK1 can serve multiple functions in signaling complexes. It is a substrate and regulator for some protein kinases and an adaptor for others. The fact that RACK1 serves as an adaptor for many other signaling proteins, including RasGAP, phospholipase Cg, PTPm, integrins, dynamin-1 and phosphodiesterase 4D5 (reviewed in Schechtman and Mochly-Rosen, 2001 ), provides further evidence for RACK1's pervasive influence on a wide array of signals that regulate diverse cellular functions.
Peptide modulators have been used successfully to elucidate the role of individual PKC isozymes in cells (Mochly-Rosen, 1995; Dorn and Mochly-Rosen, 2002 ). Our results demonstrate the potential for using peptide modulators of Src activity as a tool for uncovering the function of Src in cells. Moreover, peptide modulators that prevent or promote the interaction between signaling proteins and thereby selectively modulate their function, may have therapeutic value in human disease. Specifically, peptide inhibitors of oncogenic tyrosine kinases are potentially tumor suppressors; they represent exciting new targets for cancer therapy.
